IP To Treat PFIC Approved With Support Of Customized Research Services

A leading biopharmaceutical company working in the rare liver disease space was focused on evaluating a new drug's efficacy and safety for treating progressive familial intrahepatic cholestasis (PFIC) in a pediatric patient population. With PFIC being a highly aggressive and rare disease affecting infants and children worldwide, enrolling and supporting these vulnerable patients presented unique obstacles.

Despite the global reach of the study and the complexities of enrolling patients from various countries and language backgrounds, Elligo was brought on to design a customized recruitment plan utilizing online advertising, site recruitment support, and a study website for easy patient access. Furthermore, Elligo provided a comprehensive support continuum that included patient travel services and remote research solutions, ensuring seamless execution of the complex pediatric protocol.

Learn about the success of the study and how a suite of tailored solutions led the biopharmaceutical company to expand its partnership and solidify a full-fledged collaboration with Elligo.